Copaxone pricing boosts Teva earnings; Valeant posts $973M loss on charges;

@FiercePharma: Biggest report yesterday: Top 10 Drug Patent Losses of 2014. Feature | Follow @FiercePharma

@CarlyHFierce: Teva CEO Jeremy Levin steps down amid board squabble. Top story yesterday via FiercePharma | Follow @CarlyHFierce

> Teva Pharmaceutical Industries ($TEVA) posted better-than-expected earnings, but shares still fell on investor worries about CEO Jeremy Levin's departure. Report

> Valeant Pharmaceuticals ($VRX) reported a quarterly net loss of $973 million, which it blamed on restructuring costs and impairment charges. Report

> Adcock Ingram's largest shareholder remains undecided about Chilean drugmaker CFR Pharmaceuticals' $1.3 billion takeover offer. Report

> Denmark's Lundbeck said it expanded its partnership with Japan-based Otsuka to cover its drug for alcoholism in Japan. Report

> Hungary's Richter hiked its 2013 sales outlook on strong sales prospects in Hungary and Romania. Report

Medical Device News

@FierceMedDev: Veracyte goes public, raises $65M and gains on Day 1. Article | Follow @FierceMedDev

@MarkHFierce: Carlos Slim backs more genomics and Dx work at the Broad Institute, and elsewhere, with a new infusion of $74M. FierceDiagnostics story | Follow @MarkHFierce

@MichaelGFierce:  | Follow @MichaelGFierce

> HeartMate pump propels Thoratec revenue. More

> Elixir's dissolving stent aces 12-month study as Abbott duel looms. Story

> Abbott, Cordis-backed study challenges stent options for coronary bifurcation lesions. Item

Biotech News

@FierceBiotech: Parexel's stock plunges despite spikes in revenue, profit. Report from FierceCRO | Follow @FierceBiotech

@JohnCFierce: Feds launch probe of AstraZeneca's controversial late-stage Brilinta study. Article | Follow @JohnCFierce

@DamianFierce: Do-it-all CRO inVentiv is buying Catalina Health to boost its patient adherence business. News | Follow @DamianFierce

@EmilyMFierce: New survey details impact of federal cuts, sequestration on scientific research. FierceBiotech Research story | Follow @EmilyMFierce

> Roche looks to trump GLP-1 diabetes drugs with a combo approach. More

> Ariad shares plunge again after FDA asks for a halt to Iclusig sales. Story

> Alzheimer's experts team up with Adimab, grab $10M to launch Alector. News

Pharma Manufacturing News

@EricPFierce: Manufacturing, sanitation issues at Sanofi's Toronto vaccine plant has been a problem for some time now. Story | Follow @EricPFierce

> Foreign cancer-drug dealer gets prison. More

> Space issues lead GSK to close NJ facility, shift production. Report

> DSM opens Australia biologics plant. Story

> India renews duty on Chinese paracetamol. Article

Vaccines News

> Sanofi makes case for Fluzone superior clinical benefit label. News

> GSK, Sanofi join Gates Foundation vaccine R&D initiative. Report

> Vaccines a rare bright spot in Merck's gloomy financials. More

> ACIP recommendation gives Novartis a new growth opportunity. Story

> Dendreon reportedly seeking buyer for struggling business. Article

And Finally... The FDA found that about 12% of spices imported to the U.S. are contaminated. Report

Suggested Articles

Which rollouts might suffer most? Those that treat chronic diseases, require doctors to administer them or face current competition, analysts say.

Novartis and Incyte will put their blockbuster JAK inhibitor into phase 3 clinical trials as a possible treatment for COVID-19, the drugmakers said.

The Cannes Lions canceled its advertising creativity conference for 2020 after media reports that many large ad agencies planned to opt out.